Radiotherapy is applied to 50% of all cancer patients and is therefore an important cancer treatment modality.
Introduction
Hypoxia is a common feature of solid tumors and is known to negatively influence treatment outcome (1, 2) . Due to the disorganized vessel formation and consequently low oxygen concentrations, conventional chemotherapies and radiotherapies are less effective. To overcome hypoxia-induced treatment resistance, drugs have been developed that specifically target hypoxic tumor regions. These so-called 'hypoxia activated prodrugs' (HAP) are non-toxic under normal oxygen concentrations but are activated in environments with low oxygen concentrations. TH-302 is a second generation HAP of which the activation mechanism is based on the reduction of its 2-nitroimidazole moiety. Only in the presence of certain reductases under low oxygen concentrations is the toxic effector bromoisophosphoramide mustard (Br-IPM) selectively released and able to crosslink DNA leading to cell death.
Preclinical studies have assessed the therapeutic effect of TH-302 alone or in combination with conventional chemotherapies in multiple xenograft models. TH-302 monotherapy led to reduced tumor growth in many of the xenograft models profiled, and was dependent on the hypoxic fraction (3) . Combining TH-302 with several clinically used chemotherapeutics offers advantage over single agent treatment, although the treatment schedule and order of administration is of importance (4) . A phase 1 study demonstrated the safety of TH-302 monotherapy in patients with solid malignancies (5) . Other clinical phase I and II trials successfully combined the standard treatment doxorubicin with intravenous administration of TH-302 in patients with advanced soft tissue sarcoma (6, 7) and standard treatment gemcitabine with TH-302 in patients with advanced pancreatic cancer (8) .
However, there are no published studies to assess the combination therapy of TH-302 and radiotherapy.
Radiotherapy is one of the conventional treatment options applied to multiple cancer types and tumor hypoxia is a known radio-resistance factor. The combination of TH-302 and radiotherapy is hypothesized to be complementary;
where TH-302 specifically targets hypoxic cells, radiotherapy has the highest therapeutic gain in the welloxygenated cells.
Positron emission tomography (PET) imaging is a non-invasive method characterizing the tumor oxygenation status in a 3-dimensional manner. Several 
Materials and Methods

Animal, tumor models and treatment schedules
All animal experimental procedures were approved by the Animal Ethical Committee of Maastricht University and were in accordance with the Helsinki Declaration of 1975 as revised in 2000. All animals were monitored at least 3 times a week and their tumor volume was calculated using the formula: A x B x C x π/6 in which A, B and C are the three orthogonal diameters of the tumor as measured using a Vernier caliper, each corrected for the thickness of the skin. Animals were randomized into the different treatment groups ( Supplementary Fig. 1A ) and were monitored until 4 times start volume (T4xSV) was reached. For this calculation the start volume of the first day of TH-302 treatment was used and fitting of the data was based on the regrowth phase. TH-302 was supplied by
Threshold Pharmaceuticals and dissolved in 0.9% NaCl to a concentration of 5mg/ml. either NaCl or TH-302 (50 mg/kg) for 5 consecutive days (QDx5). Treatment was combined with RT in a single dose of 0 or 8 Gy on day 4 for which the animals were anaesthetized using a mixture of ketamine/xylazine (i.p; 66.7 and 6.7 mg/kg respectively). During the 5 days of treatment, animals were exposed to different oxygen concentrations; either a combination of nicotinamide (500mg/kg i.p.) and carbogen breathing (95% oxygen, 5% CO2), 21% oxygen breathing (pressured air) or 7% oxygen breathing (residual N 2 ). Total treatment time for all oxygen breathing schedules was 2.5 hours with the NaCl/TH-302 injection given 1 hour after the start of the treatment. Nicotinamide was administered 30 minutes before carbogen breathing was started, which was then applied for another 2 hours.
Experimental Models
RT was given within 1 hour after the oxygen treatment. Histological controls were administered with pimonidazole (60mg/kg, i.p.; Hypoxyprobe KIT, HP3-1000; Bio-connect) and Hoechst 33342 (15mg/kg, i.v.; Sigma-Aldrich) 1 hour and 1 minute before sacrificing respectively, followed by excision of the tumors which were snap-frozen in liquid nitrogen and stored at -80 degrees Celsius until being processed. Healthcare) as previously described (13) . A volume of interest in the heart (sphere with a radius of 3mm) was defined as background region. The threshold to define the hypoxic fraction (HF) was set at 4.5 times the background uptake, since this method results in a hypoxic fraction which is in agreement with the pimonidazole stainings based results of a previous study on the rat rhabdomyosarcoma model (15) .
PET Image acquisition and analysis
Immunohistochemical staining and analysis
Frozen H460 xenograft tumors were sectioned (5 µm) and stained for hypoxia (pimonidazole), blood vessels (CD31) and perfusion (Hoechst 33342). Sections were fixed using cold acetone, rehydrated in tris-buffered saline with 0.2% Tween-20 (TBST) and preincubated with normal goat serum before exposing them to the primary antibody rabbit anti-pimonidazole (1:150; HP3-1000, Bio-connect) and rat anti-mouse CD31 (1:500; BD biosciences). After washing with TBST, incubation with the secondary antibody goat anti-rabbit Alexa594 (1:500) and goat anti-rat Alexa488
(1:750, both Invitrogen) was performed. Sections were mounted using fluorescent mounting medium (DakoCytomation) and scanned for pimonidazole, blood vessels and perfusion. After scanning, sections were stained for hematoxylin and eosin (H&E).
Images were acquired using an Olympus BX51WI microscope equipped with a Hamamatsu EM-CCD C9100 digital 
Statistics
GraphPad Prism software (version 5.01 for Windows) was used to perform statistical analyses. To determine the statistical significance of differences between two independent groups of variables we used an unpaired t-test while for matched groups a paired t-test was applied. A 2-way ANOVA was performed in R v3.0.1 to determine synergistic effects. P-values <0.05 were considered to be significant. 
Results
Combination of TH-302 and radiotherapy
The effect of TH-302 in combination with RT was assessed in two tumor models, a rhabdomyosarcoma rat syngeneic model and a H460 human non-small cell lung cancer (NSCLC) xenograft mouse model. The treatment dose of TH-302 for rhabdomyosarcoma was assessed in a 'tolerability' study, showing 25mg/kg (QDx4) to be the most optimal dose without adverse effects (Supplementary Fig. 2 ). This dose was therefore selected for further experiments. The TH-302 treatment dose of 50mg/kg (QDx5) for H460 was based on literature (3).
In both tumor models TH-302 treatment showed an inhibition of the tumor growth which was further reduced when TH-302 administration was combined with a single dose of RT (8 Gy Table 1) . TH-302 has a radio-sensitizing effect in both tumor models and all RT doses. Moreover, the effect of the combination therapy TH-302 and 12Gy RT in the rhabdomyosarcoma model was even synergistic.
Hypoxic fraction
The effect of TH-302 on the hypoxic fraction (HF) in the rhabdomyosarcoma model was assessed using [ 18 F]HX4
hypoxia PET imaging and revealed a significant decrease from a baseline of 23.1% ±6.7 to 2.5% ±4.2 after TH-302 treatment (P<0.001). NaCl treatment, as expected, did not affect the HF (Fig 1C) . In the H460 model the HF was assessed immediately after the treatment using histological controls injected with pimonidazole. The HF in subjects treated with TH-302 significantly decreased compared to the control animals (NaCl: 7.8% ±3.0; TH-302: 1.3% ±0.5; Fig. 1D ).
Effect of oxygen modification on the efficacy of TH-302 and radiotherapy
To investigate if a causal relationship exists between TH-302 efficacy and tumor oxygenation, the amount of oxygen present in the tumor was modified on the days of TH-302 treatment by 7% or 95% oxygen breathing to increase or decrease the HF respectively. Oxygen modification was performed 1 day in advance for the rhabdomyosarcoma model in order to assess the effect of this modification on the baseline HF using 
reduced the T4xSV from 20.4 ±3.5 to 15.3 ±2.5 days (P=0.007, Fig. 2B, Supplementary Fig. 3C and Supplementary which is significantly delayed compared to the animals treated with NaCl (T4xSV: 16.1 ±1.9, P=0.001) although 7% oxygen treatment itself also had an effect on tumor growth in control animals. In the combination therapy of 7% oxygen breathing with RT, animals treated with TH-302 had a further reduction in the T4xSV to 35.4 ±6.1 days with an ER of 1.29 compared to the animals treated with NaCl ( Supplementary Fig. 3C and Supplementary Table 1 ).
Oxygen modification treatments were also applied to the H460 model where reducing the HF resulted in a No toxic effects were observed for the different treatments in any of the groups as monitored by following changes in body weight (Supplementary Fig. 4A&B ).
Oxygen modification and hypoxic fraction
To assess the effect of TH-302 treatment in combination with oxygen modification on the HF, a [ 18 F]HX4 scan was acquired before and after treatment on the rhabdomyosarcoma histological control animals. The HF of ambient air breathing animals decreased from 23% ±6.7 at baseline to 2.5% ±4.2 after TH-302 treatment. For 95% oxygen breathing animals the HF was low before the start of the treatment, and this remained unchanged after either NaCl or TH-302 administration (Fig. 3A) . The spread in HF of 7% oxygen breathing animals was very large. On average the HF after treatment was lower than before treatment independent of NaCl or TH-302 treatment although this was not significant.
The HF in the H460 model was determined after the last TH-302 injection using pimonidazole staining. TH-302 treatment significantly reduced the HF compared to the control animals ( Fig. 1D & 3B) . The different oxygen breathing conditions revealed a similar pattern; in combination with 95% oxygen breathing control animals had a HF of 10.0% ±5.9 while animals treated with TH-302 had a HF of 2.1% ± 1.0. Animals exposed to low oxygen concentrations in combination with NaCl had a HF of 8.4% ±4.5 which was lower in the animals treated with TH-302 (1.1% ±1.0). Furthermore, TH-302-treated tumors had a decreased necrotic fraction, although this was only significant when animals were exposed to 21% oxygen. No differences were observed in the relative vessel area or perfusion ( Supplementary Fig. 5 ).
Furthermore, we investigated whether the HF at the start of the therapy was associated with the treatment outcome expressed as T4xSV. The T4xSV for TH-302 treated tumors increased with increasing HF at onset meaning that 95% oxygen breathing animals reached their endpoint first, followed by ambient air and then 7% oxygen breathing animals (Fig. 4) . The control animals, with or without radiotherapy, did not show this association.
Research. 
Discussion
This study demonstrates the combination efficacy of the hypoxia-activated prodrug TH-302 with radiotherapy in two preclinical tumor models, which was causally related to the tumor oxygen status. Additionally, the [ 18 F]HX4 determined hypoxic fraction (HF) was associated with the treatment outcome.
Pharmacokinetic studies in non-tumor bearing rats showed no adverse effects when the animals were treated with TH-302 (17) . Although rhabdomyosarcoma-bearing rats showed no adverse effect after a 25 mg/kg TH-302 dose, dose-dependent adverse effects, such as a significant drop in body weight, diarrhea and general malaise, were observed after higher dosing. Initial clinical studies also reported some adverse effects with skin and mucosal toxicities being dose limiting, while common adverse events were nausea, skin rash, fatigue and vomiting (5, 6).
In this study two different methods were used to assess the HF: non-invasive, clinically used [ 18 F]HX4 PET imaging (11, 13) , and immunohistochemistry of pimonidazole adducts (9 (19, 20) .
A correlation has previously been reported between the HF and the tumor growth inhibition in xenograft models (3) . This endorses our findings of a pronounced effect of TH-302 since the preclinical tumor models in this study were observed to have respectively somewhat higher and lower HF than the reported HF of 18.6% for rhabdomyosarcoma (15) 
Although TH-302 exhibits anti-tumor effects as a monotherapy, it has been shown that its therapeutic efficacy increases when combined with conventional anticancer therapies mainly targeting the non-hypoxic cells. Based on favorable outcomes of two clinical phase II trials (7, 8) , phase III trials in metastatic or locally advanced unresectable pancreatic adenocarcinoma (NCT01746979) and advanced soft-tissue sarcoma (NCT01440088) are currently ongoing. However, to our knowledge, no study has investigated the combination treatment of TH-302 with radiotherapy and [
18 F]HX4 hypoxia imaging. This combination is thought to be effective especially since RT can be locally applied, specifically targeting the tumor while preserving normal tissue. In this study we show that this combination is effective and causes a delayed tumor growth and increased T4xSV for both investigated tumor models, confirming the hypothesis that the combination therapy of TH-302 and RT will lead to an enhanced therapeutic effect. In the rhabdomyosarcoma tumor model, TH-302 treatment was combined with a single dose of 4, 8 and 12Gy of RT resulting in a dose dependent effect. In subsequent studies the single RT dose of 8Gy was used, reasoning that the regrowth of the tumor solely depends on hypoxic cells (21), providing a basis for TH-302 efficacy.
This approach is different from clinical practice where fractionated radiotherapy schedules are used. By applying 2Gy fractions to the tumor, reoxygenation occurs and the HF gradually decreases (22, 23) . We speculate that the combination of TH-302 with fractionated radiotherapy would also increase the therapeutic effect of the RT since the HF is reduced by the pretreatment of TH-302, increasing the potential of RT.
In this study we further wanted to elucidate if TH-302 efficacy is dependent on the tumor oxygen status. Exposing animals to either nicotinamide and carbogen or 7% oxygen breathing has been demonstrated to be effective in modulating the HF in tumors (9, 24, 25) . Altering oxygen breathing before the TH-302 treatment did modify the tumor HF in rhabdomyosarcoma animals as measured by [ 18 F]HX4. However, in the H460 model, the HF was only determined after TH-302 treatment and at this point no differences were observed in control animals of the various oxygen modifications. A possible explanation would be that the mice adapted to the oxygen breathing schedule, preventing the tumor HF from changing, which has been observed for mice exposed to long-term carbogen breathing (26, 27) . In the rhabdomyosarcoma model, the tumor growth of control animals was significantly reduced upon oxygen modification as well as in the mice exposed to 7% oxygen breathing mice. No effect on tumor growth was observed after oxygen modification in another study using H460 tumors exposed to 95% or 10% oxygen breathing (3). This unexpected finding could possibly be explained by the stress induced by the exposure to the oxygen modifications, although TH-302 or RT treatment groups did not seem to be influenced by this. However, by calculating the enhancement ratio these oxygen modification effects are taken into account. Despite these effects on growth delay a positive effect of the therapy is observed. Radiotherapy was applied 1 hour after carbogen breathing without any beneficial effect. This can be explained by the fact that tumor oxygen concentrations return to pre-carbogen levels within 1 minute after stopping carbogen treatment as detected by
Eppendorf electrode measurements (28) . Furthermore, clinical studies have shown that the presence of hypoxia increasing the HF, we speculate that it is caused by a limited availability of TH-302 to target all hypoxic cells. In H460 tumors, 7% oxygen breathing resulted in an increased therapeutic effect with an enhancement ratio of 2.2 for TH-302 alone and 2.5 for the combination therapy of TH-302 and RT. This result demonstrates that when sufficient TH-302 is present, more TH-302 is reduced upon low oxygen concentrations, causing an increased cytotoxicity.
A causal relation between the pretreatment HF measured by [ 18 F]HX4 and the TH-302 treatment outcome was observed. These results indicate that pretreatment evaluation of hypoxia could be a useful tool in selecting tumors that benefit from the additional hypoxia targeting treatment. This hypoxia-based patient selection could also be used in other therapy strategies for instance to target hypoxic subvolumes by escalate radiation dose (31) .
Furthermore this information could be implemented in decision-support systems to predict tumor response and optimize patient therapy (32) . These applications demonstrate the importance of gaining pretreatment information by hypoxia imaging.
Conclusion
This study demonstrates that TH-302 treatment together with conventional radiotherapy is a promising combination with an increased therapeutic potential, and warrants further testing. Furthermore, detecting the tumor hypoxic fraction by [ The combination of TH-302 and radiotherapy reduces tumor growth (RT; 8Gy) in a rhabdomyosarcoma (n=8) and H460 (n≥8) tumor model presented in A) growth curves and B) time to reach 4 times start volume (T4xSV). Animals were treated with either control (NaCl) or TH-302 administered to the rhabdomyosarcoma model for 4 consecutive days with a dose of 25mg/kg and for the H460 model for 5 consecutive days using a 50mg/kg dose. RT was applied on either the 3rd or 4th day of TH-302 treatment.
The hypoxic fraction of the control animals and the animals treated with TH-302 were analyzed in C) for rhabdomyosarcoma (n=6) both before and immediately after treatment using [ Research. 
